Market Research Report
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
|Alzheimer's Disease Therapeutics and Diagnostics: Global Markets|
Published: November 27, 2020
Content info: 88 Pages
Delivery time: 1-2 business days
The global market for Alzheimer’s disease treatment should grow from $4.8 billion in 2020 to $6.3 billion by 2025 with a compound annual growth rate (CAGR) of 5.5% during the period of 2020-2025.
The North American market for Alzheimer’s disease treatment should grow from $2.5 billion in 2020 to $3.3 billion by 2025 with a CAGR of 5.6% during the period of 2020-2025.
The Asia-Pacific market for Alzheimer’s disease treatment should grow from $1.3 billion in 2020 to $1.7 billion by 2025 with a CAGR of 5.6% during the period of 2020-2025.
The scope of this study encompasses the global and regional markets for Alzheimer's therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (AB) vaccines. Drugs are also segmented by the stage of Alzheimer's disease they treat, i.e., mild to moderate, severe and prodromal.
BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe, Asia-Pacific and Rest of the world (RoW).